A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies
A Phase IA/II Multicenter, Dose-escalation Study of Oral AMN107 on a Continuous Daily Dosing Schedule in Adult Patients With Imatinib-resistant/Intolerant CML in Chronic or Accelerated Phase or Blast Crisis, Relapsed/Refractory Ph+ ALL, and Other Hematologic Malignancies.
Sponsor: Novartis Pharmaceuticals
This PHASE1/PHASE2 trial investigates Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive) and Chronic Myelogenous Leukemia and is currently completed. Novartis Pharmaceuticals leads this study, which shows 10 recorded versions since 2005 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
10 versions recorded-
Jan 2026 — Present [monthly]
Completed PHASE1/PHASE2
-
Sep 2025 — Present [monthly]
Completed PHASE1/PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Sep 2021 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
▶ Show 5 earlier versions
-
Jan 2021 — Sep 2021 [monthly]
Completed PHASE1_PHASE2
-
Mar 2020 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
-
Jun 2018 — Mar 2020 [monthly]
Completed PHASE1_PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE1_PHASE2
First recorded
Apr 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Novartis Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .